be important to assess the long-term impact of NET inhibition on the tumor immune landscape and immunotherapy response to shed light on these outstanding questions.In summary, Teijeira et al. demonstrate a requirement for CXCR-1 and -2 receptor activation in NET induction and a novel role for NETs as a physical shield between human tumor cells and cytotoxic lymphocytes-specifically CD8 + T cells and NK cells (Figure 1). The results of this study highlight an exciting therapeutic approach suggesting that NET blockade may allow immune cells to ''peNETrate'' the tumor microenvironment and ultimately promote the efficacy of immunotherapy.

No abstract

Whereas interleukin-6 (IL-6) is a proinflammatory cytokine, IL-10 is an anti-inflammatory cytokine. Although signal transducer and activator of transcription 3 (STAT3) is essential for the function of both IL-6 and IL-10, it is unclear how these two cytokines have such opposing functions. Here we show that suppressor of cytokine signaling 3 (SOCS3) is a key regulator of the divergent action of these two cytokines. In macrophages lacking the Socs3 gene or carrying a mutation of the SOCS3-binding site in gp130, the lipopolysaccharide-induced production of tumor necrosis factor (TNF) and IL-12 is suppressed by both IL-10 and IL-6. SOCS3 specifically prevents activation of STAT3 by IL-6 but not IL-10. Taken together, these data indicate that SOCS3 selectively blocks signaling by IL-6, thereby preventing its ability to inhibit LPS signaling.

Memory T cells maintain their numbers for long periods after antigen exposure. Here we show that CD8+ T cells of memory phenotype divide slowly in animals. This division requires interleukin-15 and is markedly increased by inhibition of interleukin-2 (IL-2). Therefore, the numbers of CD8+ memory T cells in animals are controlled by a balance between IL-15 and IL-2.